Recent Updates
Recently added Catalysts
BHC

Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces the Unrestric

Key Takeaway: Investor Contact: Media Contacts: Christina Cheng Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (514) 856-3855 (848) 541-3785 (877) 281-6642 (toll free) Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Docume

Full Press Release Details

Investor Contact: Media Contacts:
Christina Cheng Kevin Wiggins
ir@bauschhealth.com corporate.communications@bauschhealth.com
(514) 856-3855 (848) 541-3785
(877) 281-6642 (toll free)
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
LAVAL, Quebec, Nov. 29, 2022 Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) has designated 1261229
B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ( Bausch + Lomb ), as an unrestricted subsidiary of the Company in accordance with the terms of the
Company s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the
covenants under the Bausch Health debt documents.
The Company continues to evaluate potential options to maximize stakeholder value, which include its
ongoing focus on its balance sheet and liquidity.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people s lives with our health
care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our
leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This news release may contain
forward-looking statements about the future performance of Bausch Health including the proposed plan to fully separate its eye health business, including the timing thereof, which may generally be identified by the use of the words
anticipates, hopes, expects, intends, plans, should, could, would, may, believes, subject to and variations or
similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health s overall business, including those more fully described in Bausch Health s most recent annual report on Form
10-K and detailed from time to time in Bausch Health s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by
Last updated: Nov 29, 2022